**IJABPT** ISSI

Short communication

### GENISTEIN DIMINISHED CIZ1 EXPRESSION IN DAUDI LYMPHOID CELLS.

Naoko Okumura, Yuka Nagata, Hitomi Yoshida, Yuri Nishimura, Yasuko Kitagishi, Satoru Matsuda\*

\*Department of Environmental Health Science, Nara Women's University, Nara 630-8506, Japan.

TEL: +81 742 20 3451; FAX: +81 742 20 3451; E-mail: smatsuda@cc.nara-wu.ac.jp

**ABSTRACT :** Cip-interacting zinc finger protein 1 (Ciz1), stimulates DNA replication and has been implicated in tumorigenesis of breast cancer cells. In order to investigate the possibility of using medicinal isoflavone agaist breast cancer, we studied whether some isoflavones could affect the expression of the Ciz1. The *in vitro* effect of isoflavone treatment on the reduction of Ciz1 expression was detected by reverse transcriptase-polymerase chain reaction (RT-PCR). Western blotting also confirmed the down-regulation of the protein at dose dependent manner of the genistein treatment in Daudi lymphoid cell line cells.

Keywords: isoflavone, genistein, gene expression, Ciz1, breast cancer

### INTRODUCTION

Breast cancer is the most commonly diagnosed cancer in women and is a major cause of cancer deaths (Jemal A, et. a1., 2008). A large number of previous works have provided insight about the roles of cell cycle components in transcriptional stimulation by estrogen in the breast cancer cells. The transcriptional activity of the estrogen receptor (ER) is affected by regulatory cofactors including coactivators and corepressors. Among them, Ciz1 stimulates DNA replication depending on ER and participates in the regulation of cell cycle by increasing cdk2 kinase activity and inducing the G1-Stransition (den Hollander P, et. al., 2006). Ciz1 protein coregulates ER by enhancing its transactivation activity and recruitment to target gene chromatin. Hypersensitivity to estrogen has been observed in patients with breast cancer (Santen RJ, et. al., 2005). Ciz1 induces such the hypersensitivity of breast cancer cells to estrogen and induces the expression of ER target gene cyclin D1. Then,overexpression of Ciz1 promoted the growth-rate, anchorageindependence and tumorigenesis of breast cancer cells (den Hollander P, et. al., 2006). Accordingly, repression of Ciz1 expression may be expected to have interference effects on breast cancer progression.

# International Journal of Applied Biology and Pharmaceutical Technology Page:1040 Available online at <u>www.ijabpt.com</u>

#### Satoru Matsuda et al

### IJABPT

### ISSN 0976-4550

Bio-properties of dietary soy have been suggested in numerous studies. Isoflavones present in soy have been shown to be bioactive compounds. When significant quantities of isoflavones are consumed, their bioactivity has been proposed to favorably affect blood lipid levels, symptoms of menopause, and osteoporosis (Demonty I, et. al., 2003, Zhan S, et. al., 2005). Isoflavones may exert an effect at least in part by modifying the activity of certain factors. For example, isoflavones have been shown to affect metabolisms via the activation of PPAR (Dang ZC, et. al., 2003, Kim S, et. al., 2004,) and affect the expression of HMG-CoA reductase through sterol regulatory element binding protein regulation in HepG2 cells (Mullen E, et. al., 2004). The protective effects of soy observed with respect to cardiovascular disease and bone and menopausal health may in part be due to the regulation of transcriptional expression of certain enzymes (Setchell KD, et. al., 2002).


Investigation of variations in gene expression as a result of isoflavone treatment might help define the underlying mechanisms of soy actions. We then hypothesized that some isoflavones could affect the expression of the Ciz1.

#### **RESULTS AND DISCUSSION**

In order to investigate the possibility of using medicinal phytochemicals, isoflavone, estradiol, as well as dexamethasone were added into cell culture medium of K562, Jurkat or Daudi cells and the levels of Ciz1expression were examined. Aglycone form of isoflavone was used for the experiment. We first employed RT-PCR analysis to quantify the expression level of Ciz1 gene. Total RNA was isolated 24 hr after treatment for detection of Ciz1, and the levels of mRNA were determined by the conventional RT-PCR. As shown in Figure 1, the Ciz1 gene expression level greatly decreased in the treatment of isoflavone at the final concentration 10<sup>-5</sup> M, compared with the untreated ethanol vehicle, estradiol and dexamethasone, in the Daudi cells. On the contrary, the expression of the housekeeping gene GAPDH was unaltered. There was almost no difference on the results of gene expressional profile between Daudi and Jurkat cells, and no reduction of Ciz1 expression in K562 cells. To exclude the possibility of carry-over contamination, reactions containing all RT-PCR reagents including primers without sample RNA were preformed as negative controls. No such RNA contamination was detected (data not shown).


To further confirm the expression status of Ciz1 reduced by the isoflavone, western method was also performed to analyze the level of Ciz1 protein in the Daudi cells. As shown in Figure 2A, the isoflavone, genistein, but not daidzein treatment also diminished the protein expression of Ciz1. This protein expression profile approximately agreed with the result of RT-PCR shown in Figure 1. We then addressed a question whether the genistein can reduce Ciz1 expression at dose dependent manner. After pre-treating the cells with a set of different dose of concentrations of the genistein, we found that Ciz1 protein expression was decreased with the increasing concentrations of the genistein. As shown in Figure 2B, final concentration 10<sup>-6</sup> M l of the genistein diminished the Ciz1 expression by more than 90% in the Daudi cells after 96 hr genistein stimulation.

International Journal of Applied Biology and Pharmaceutical TechnologyPage:1041 Available online at <u>www.ijabpt.com</u>




**Figure 1.**Ciz1 mRNA was analyzed by semi-quantitative RT-PCR. The semiquantitative RT-PCR was performed using primers specific to Ciz1 (Fw : 5'-ACATATCCACAGGTCCACACAC-3',

Rv : 5'-CTGCTCATGGGTCTGCTCTG-3') or GAPDH control (Fw: 5'-TCCCATCACCATCTTCCA-3', Rv : 5'-CATCACGCCACAGTTTCC-3') on 100 ng total RNA prepared from Daudi cells treated without (lane 1, lane 5) or with dexamethasone (SIGMA) (lane 2, lane 6), estradiol (SIGMA) (lane 3, lane 7), isoflavone (INDOFINE chemical) (lane 4, lane 8) at the final concentration  $10^{-5}$  M for 24 hr. The Daudi cells were maintained in RPMI1642 supplemented with 10 % fetal bovine serum, penicillin and streptomycin at 37°C in a humidified atmosphere containing 5 % CO<sub>2</sub>. Aglycone form of isoflavone was used for the experiment. Specific expression was determined in relation to the expression of the housekeeping gene GAPDH used as an internal loading control. At least four independent experiments were done, and typical two paired results were documented.



**Figure 2A.**Genistein diminished the expression of Ciz1 protein. Daudi cells were treated without (lane 1) or with dexamethasone (lane 2), estradiol (lane 3), isoflavone (lane 4), genistein (Cayman Chemical) (lane 5), daidzein (Cayman Chemical) (lane 6) at the final concentration 10<sup>-5</sup> M for 48 hr. After treatment, cell lysates were isolated, the levels of Ciz1 protein was detected by western blot analysis using anti-Ciz1 antibody (COSMO BIO). Western blot with anti-Erk2 antibody (BD Bioscience) was also shown as equal levels of protein loading.

International Journal of Applied Biology and Pharmaceutical TechnologyPage:1042 Available online at <u>www.ijabpt.com</u>



**Figure 2B.**Dose dependent repression of Ciz1 protein expression. Daudi cells were treated without (lane 1, 5) or with genistein at the final concentration  $10^{-6}$  M (lane 2, 6),  $10^{-5}$  M (lane 3, 7),  $10^{-4}$  M (lane 4, 8) for 48 hr (lane 1, 2, 3, 4) or 96 hr (lane 5, 6, 7, 8). The levels of Ciz1 protein were detected by western blot analysis using anti-Ciz1 antibody as figure 2A. Western blot with anti-Erk2 antibody was also shown as equal levels of protein loading.

Many of phytochemicals present in a wide variety of plants might preferentially interact with ER among the hormone receptors belonging to the nuclear receptor superfamily (Takeuchi S, et. al., 2009). There are a number of *in vitro* studies of the estrogenic properties specially genistein and daidzein.( Mueller S. O., et. al., 2004, Harris D. M., et. al., 2005) These are structurally similar to estrogen and genistein and daidzein, but not glycitein, can bind to and transactivate ER (Chrzan BG, et. al., 2007, Sakamoto T, et. al., 2010). Soy isoflavones are present in soy foods as aglycones where genistein, daidzein, and glycitein make up 50%, 40%, and 10%, respectively, of the total soybean isoflavones (Murphy PA, et. al., 1999). Recent data indicate that genistein inhibits invasion, metastasis, and angiogenesis in vitro and in vivo in a number of cancers including breast cancer (Singh AV, et. al., 2005, Vantyghem SA, et. al., 2005). However, other studies have shown that daidzein increased while genistein decreased mammary tumor growth compared to vehicle, respectively(Martínez-Montemayor MM, et. al., 2010). Moreover, the contradictory result that genistein increased the growth of MCF-7 human breast cancer cells and tumors in ovariectomized nude mice and metastatic progression of prostate cancer has also been reported (El Touny LH, et. al., 2009, Jeng YJ, et. al., 2009).

Genistein affects cellular function via inhibition of tyrosine protein kinases, cycloxygenase 2 and cytochrome p450 enzymes (Rice S, et. al., 2006, Shon YH, et. al., 2006). Genistein also modulates ER levels, the activity of topoisomerase II, enzymes involved in phospho-inositide turnover, mitogen activated protein kinases and NF-kappaB signaling pathways (Singh AV, et. al., 2006, Rabiau N, et. al., 2010). Here, we show that genistein is the potent transcriptional repressor for Ciz1 gene. The precise mechanism of transcriptional regulation of Ciz1 by genistein remains unclear. The Ciz1 gene might be complicatedly regulated by various transcription factors. More studies including in vivo experiments need to be undertaken to elucidate the molecular mechanisms of the isoflavone.

International Journal of Applied Biology and Pharmaceutical TechnologyPage:1043 Available online at <u>www.ijabpt.com</u>

# **WABPT**

This work was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology in Japan.

Competing interests statement: The authors declared that no conflict of interest exists.

#### REFERENCES

Chrzan BG, Bradford PG. (2007) Phytoestrogens activate estrogen receptor beta1 and estrogenic responses in human breast and bone cancer cell lines. Mol Nutr Food Res. 51:171–177.

Dang ZC, Audinot V, Papapoulos SE, Boutin JA, Lowik CW. (2003). Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J Biol Chem. 278:962–967.

Demonty I, Lamarche B, Jones PJ. (2003). Role of isoflavones in the hypocholesterolemic effect of soy. Nutr Rev. 61:189–203.

den Hollander P, Rayala SK, Coverley D, Kumar R. (2006). Ciz1, a Novel DNA-binding coactivator of the estrogen receptor alpha, confers hypersensitivity to estrogen action. Cancer Res. 66:11021-11029.

El Touny LH, Banerjee PP. (2009). Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res. 69:3695–3703.

Harris D. M., Besselink E., Henning S. M., Go V. L., Heber D. (2005). Phytoestrogens induce differential estrogen receptor alpha- or Beta-mediated responses in transfected breast cancer cells. *Exp. Biol. Med.*, 230:558-568.

Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. (2008). Cancer statistics, 2008. CA Cancer J Clin 5:71–96.

Jeng YJ, Watson CS. (2009). Proliferative and anti-proliferative effects of dietary levels of phytoestrogens in rat pituitary GH3/ B6/F10 cells—the involvement of rapidly activated kinases and caspases. BMC Cancer 9:334.

Kim S, Shin HJ, Kim SY, Kim JH, Lee YS, Kim DH, Lee MO. (2004). Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARalpha. Mol Cell Endocrinol. 220:51–58.

Martínez-Montemayor MM, Otero-Franqui E, Martinez J, De La Mota-Peynado A, Cubano LA, Dharmawardhane S. (2010). Individual and combined soy isoflavones exert differential effects on metastatic cancer progression. Clin Exp Metastasis. 27:465-480.

Mullen E, Brown RM, Osborne TF, Shay NF.(2004). Soy isoflavones affect sterol regulatory element binding proteins (SREBPs) and SREBPregulated genes in HepG2 cells. J Nutr. 134:2942–2947.

Mueller S. O., Simon S., Chae K., Metzeler M., Korach K. S. (2004). Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells., *Toxicol. Sci.*, 80:14-25.

Murphy PA, Song T, Buseman G, Barua K, Beecher GR, Trainer D, Holden J (1999). Isoflavones in retail and institutional soy foods. J Agric Food Chem. 47:2697–2704.

## International Journal of Applied Biology and Pharmaceutical TechnologyPage: 1044 Available online at <u>www.ijabpt.com</u>

### Satoru Matsuda et al

# <u>IJA'B</u>PT

Rabiau N, Kossai M, Braud M, Chalabi N, Satih S, Bignon YJ, Bernard-Gallon DJ. (2010). Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by Polymerase Chain Reaction arrays in human prostate cancer cell lines. Cancer Epidemiol 34:200–206.

Rice S, Whitehead SA. (2006). Phytoestrogens and breast cancer— promoters or protectors? Endocr Relat Cancer 13:995–1015.

Sakamoto T, Horiguchi H, Oguma E, Kayama F. (2010). Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells. J Nutr Biochem. 2010 21:856-864.

Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Lawrence J Jr, MacMahon LP, Yue W, Berstein L. (2005). Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 95:155–165.

Setchell KD, Brown NM, Lydeking-Olsen E. (2002). The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. 132:3577–3584.

Shon YH, Park SD, Nam KS. (2006). Effective chemopreventive activity of genistein against human breast cancer cells. J Biochem Mol Biol 39:448–451.

Singh AV, Franke AA, Blackburn GL, Zhou JR. (2006). Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res 66:1851–1858.

Takeuchi S, Takahashi T, Sawada Y, Iida M, Matsuda T, Kojima H. (2009). Comparative study on the nuclear hormone receptor activity of various phytochemicals and their metabolites by reporter gene assays using Chinese hamster ovary cells. Biol Pharm Bull. 32:195-202.

Vantyghem SA, Wilson SM, Postenka CO, Al-Katib W, Tuck AB, Chambers AF. (2005). Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model. Cancer Res 65:3396–3403.

Zhan S, Ho SC. (2005). Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr. 81:397–408.

#### \*\*\*\*\*\*

International Journal of Applied Biology and Pharmaceutical TechnologyPage:1045 Available online at <u>www.ijabpt.com</u>